Intrinsiqq
Kala Pharmaceuticals, Inc. logo

Kala Pharmaceuticals, Inc. Financials

KALA

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 12 available years
Income Statement
TTM
DEC 2025
2:1 split
DEC 2024
~1.6:1 split
DEC 2023
~1.6:1 split
DEC 2022
~1013.7:1 split
DEC 2021
Revenues
Revenue$4$0$0$0$4$11
General & Administrative$65$24$18$21$65$105
Research & Development$18$19$22$19$18$12
Other Operating Expenses–––––-$12
Total Operating Expenses$86$39$41$40$86$141
Operating Income-$82-$39-$41-$40-$82-$130
Non-Operating
Net Interest Expense-$7-$2-$4-$3-$7-$8
Other Non-Operating Income (Expense)$37$12$2-$3$37-$12
Income Tax Expense–$0$0$0$0$0
Net Income
Net Income-$45-$27-$39-$42-$45-$143
Per Share Data
Revenue Per Share$3,839.25$0.00$0.00$0.00$3,839.25$12,928.89
EPS (Basic)-$44,220.00-$4,965.00-$15,225.00-$26,025.00-$44,220.00-$162,480.00
EPS (Diluted)-$44,220.00-$4,965.00-$15,225.00-$26,025.00-$44,220.00-$162,480.00
Weighted Avg Shares (Basic)1.5M8.1M3.8M2.4M1.5M65.2M
Weighted Avg Shares (Diluted)1.5M8.1M3.8M2.4M1.5M65.2M
Shares Outstanding1,013.7415,432.1832,530.6981,621.3391,013.741869.371

Kala Pharmaceuticals (KALA) financials: revenue, profit and margins

Kala Pharmaceuticals (KALA) generated about n/a in revenue and -$10 million in net income over the trailing twelve months, growing at roughly 205.0% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Kala Pharmaceuticals profitable?+

Kala Pharmaceuticals reported about -$10 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Kala Pharmaceuticals growing?+

Kala Pharmaceuticals's revenue has compounded at roughly 205.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside KALA's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 19 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 22 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KALA

CompareIntrinsic value
PRPHProPhase Labs Inc.
$0.01-42.00%0
TRDAEntrada Therapeutics Inc.
$4.35-6.25%10
TXMDTherapeuticsMD, Inc.
$1.71-5.52%29
LPCNLipocine Inc.
$1.50+0.00%40
ATAIAtaiBeckley Inc.
$0.53-25.36%40
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
MRKRMarker Therapeutics, Inc.
$1.11-15.91%25
PSTVPlus Therapeutics Inc
No recent price20

Spot a number that looks wrong? Check it in KALA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KALA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.